The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma
Abstract
A previous placebo-controlled trial has shown that biodegradable 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU) wafers (Gliadel wafers) prolong survival in patients with recurrent glioblastoma multiforme. A previously completed phase 3 trial, also placebo controlled, in 32 patients with newly diagnosed malignant glioma also demonstrated a survival benefit in those patients treated with BCNU wafers. Because of the small number of patients in that trial, a larger phase 3 trial was performed to confirm these results. Two hundred forty patients were randomized to receive either BCNU or placebo wafers at the time of primary surgical resection; both groups were treated with external beam radiation postoperatively. The two groups were similar for age, sex, Karnofsky performance status (KPS), and tumor histology. Median survival in the intent-to-treat group was 13.9 months for the BCNU wafer-treated group and 11.6 months for the placebo-treated group (log-rank P -value stratified by country = 0.03), with a 29% reduction in the risk of death in the treatment group. When adjusted for factors affecting survival, the treatment effect remained positive with a risk reduction of 28% ( P = 0.03). Time to decline in KPS and in 10/11 neuroperformance measures was statistically significantly prolonged in the BCNU wafer-treated group ( P </= 0.05). Adverse events were comparable for the 2 groups, except for CSF leak (5% in the BCNU wafer-treated group vs. 0.8% in the placebo-treated group) and intracranial hypertension (9.1% in the BCNU wafer-treated group vs. 1.7% in the placebo group). This study confirms that local chemotherapy with BCNU wafers is well tolerated and offers a survival benefit to patients with newly diagnosed malignant glioma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer: Principles and Practice of Oncology.
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-9-819_4 · Cited by 8,516
World Health Organization Classification of Tumours
Fletcher, C., van den Berg, A., & Molenaar, I. (2002) · Cited by 7,079
Walker, M. D., Green, S. B., Byar, D. P., Alexander, E., Batzdorf, U., Brooks, W. H., Hunt, W. E., MacCarty, C. S., Mahaley, M. S., Mealey, J., et al. (1980) · New England Journal of Medicine · doi:10.1056/nejm198012043032303 · Cited by 1,611
Culver, K. W., Ram, Z., Wallbridge, S., Ishii, H., Oldfield, E. H., & Blaese, R. M. (1992) · Science · doi:10.1126/science.1317968 · Cited by 1,509
Self-citationPathology and genetics of tumours of the nervous system.
Kleihues, P., & Cavennee, W. (2000) · International Agency for Research on Cancer eBooks · Cited by 1,432
Brem, H., Piantadosi, S., Burger, P. C., Walker, M., Selker, R., Vick, N. A., Black, K., Sisti, M., Brem, S., Mohr, G., et al. (1995) · The Lancet · doi:10.1016/s0140-6736(95)90755-6 · Cited by 1,389
Assumptions in the radiotherapy of glioblastoma
Hochberg, F. H., & Pruitt, A. (1980) · Neurology · doi:10.1212/wnl.30.9.907 · Cited by 992
Rainov, N. G. (2000) · Human Gene Therapy · doi:10.1089/104303400750038499 · Cited by 698
Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells
Ram, Z., Culver, K. W., Oshiro, E. M., Viola, J. J., DeVroom, H. L., Otto, E., Long, Z., Chiang, Y., McGarrity, G. J., Muul, L. M., et al. (1997) · Nature Medicine · doi:10.1038/nm1297-1354 · Cited by 668
Self-citationGlioma Invasion in the Central Nervous System
Giesexs, A., & Westphal, M. (1996) · Neurosurgery · doi:10.1097/00006123-199608000-00001 · Cited by 583
Self-citationLaske, D. W., Youle, R. J., & Oldfield, E. H. (1997) · Nature Medicine · doi:10.1038/nm1297-1362 · Cited by 525
Valtonen, S., Timonen, U. L., Toivanen, P., Kalimo, H., Kivipelto, L., Heiskanen, O., Unsgaard, G., & Kuurne, T. (1997) · Neurosurgery · doi:10.1097/00006123-199707000-00011 · Cited by 426
Mesnil, M., Piccoli, C., Tiraby, G., Willecke, K., & Yamasaki, H. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.5.1831 · Cited by 411
Convection-enhanced distribution of large molecules in gray matter during interstitial drug infusion
Lieberman, D. M., Laske, D. W., Morrison, P. F., Bankiewicz, K. S., & Oldfield, E. H. (1995) · Journal of Neurosurgery · doi:10.3171/jns.1995.82.6.1021 · Cited by 341
Shapiro, W. R., Green, S. B., Burger, P. C., Selker, R. G., VanGilder, J. C., Robertson, J. T., Mealey, J., Ransohoff, J., & Mahaley, M. S. (1992) · Journal of Neurosurgery · doi:10.3171/jns.1992.76.5.0772 · Cited by 243
Jachimczak, P., Bogdahn, U., Schneider, J., Behl, C., Meixensberger, J., Apfel, R., Dörries, R., Schlingensiepen, K.-H., & Brysch, W. (1993) · Journal of Neurosurgery · doi:10.3171/jns.1993.78.6.0944 · Cited by 146
Modulation of the Immune Response by Transforming Growth Factor Beta
Fontana, A., Constam, D. B., Frei, K., Malipiero, U., & Pfister, H. (2009) · International Archives of Allergy and Immunology · doi:10.1159/000236328 · Cited by 146
Brem, H., Tamargo, R. J., Olivi, A., Pinn, M. L., WEINGART, J. D., Wharam, M. D., & Epstein, J. I. (1994) · Journal of neurosurgery · doi:10.3171/jns.1994.80.2.0283 · Cited by 144
Cairncross, J. G., Macdonald, D. R., & Ramsay, D. A. (1992) · Neurosurgery · doi:10.1097/00006123-199207000-00011 · Cited by 130
Kramm, C. M., Sena‐Esteves, M., Barnett, F. H., Rainov, N. G., Schuback, D. E., Yu, J. S., Pechan, P. A., Paulus, W., Chiocca, E. A., & Breakefield, X. O. (1995) · Brain Pathology · doi:10.1111/j.1750-3639.1995.tb00615.x · Cited by 103
Wersäll, P. J., Ohlsson, I., Biberfeld, P., Collins, V. P., von Krusenstjerna, S., Larsson, S., Mellstedt, H., & Boethius, J. (1997) · Cancer Immunology Immunotherapy · doi:10.1007/s002620050368 · Cited by 75
Clinical trial end points in malignant glioma: need for effective trial design strategy.
Brada, M., & Yung, W. K. A. (2000) · PubMed · Cited by 28
Cited by
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Wen, P. Y., & Kesari, S. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0708126 · Cited by 3,511
Glioblastoma and Other Malignant Gliomas: A Clinical Review
Omuro, A. (2013) · JAMA · doi:10.1001/jama.2013.280319 · Cited by 2,301
EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
Weller, M., van den Bent, M., Preusser, M., Le Rhun, E., Tonn, J. C., Minniti, G., Bendszus, M., Balana, C., Chinot, O., Dirven, L., et al. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00447-z · Cited by 2,048
Self-citationPolymer conjugates as anticancer nanomedicines
Duncan, R. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1958 · Cited by 1,962
Metadata
- Authors
- Westphal, M., Hilt, D. C., Bortey, E., Delavault, P., Olivares, R., Warnke, P. C., Whittle, I. R., Jääskeläinen, J., & Ram, Z.
- Venue
- Neuro-Oncology
- Publisher
- Oxford University Press (OUP)
- Published
- 2003-04-01
- Volume
- 5
- Issue
- 2
- Pages
- 79-88
- ISSN
- 1522-8517 (ISSN-L)
- 1523-5866
- OpenAlex
- W2100567246
- Cited by
- 1,330
- References
- 23
- FWCI
- 24.36
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.